Treatment of the pregnant mother with cancer: A systematic review on the use of cytotoxic, endocrine, targeted agents and immunotherapy during pregnancy. Part II: Hematological tumors

Adolescent and Young Adult Oncology, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology

“…154 Cervical, breast, thyroid, and ovarian cancers, melanoma, lymphoma, and leukemia are the most common cancers diagnosed during pregnancy. [155][156][157][158] These are also the most common cancers diagnosed in the AYA population. 159 An analysis of 1963 to 2007 data from the Swedish Multi-Generation Register and the National Cancer Register showed a lower-than-expected number of cancers diagnosed during pregnancy, and a rebound in the number of cases of melanoma, CNS cancers, breast cancer, and thyroid cancer in postpartum women.…”

Hematologic Malignancies in Pregnancy

“…A stillborn fetus was reported in one case after exposure to daunorubicin. Congenital anomalies including limb deformities, ventral septal defect and cardiomyopathy were also reported (Azim et al, 2010). Doxorubicin has been extensively studied in gestational breast cancer and results are rather reassuring (Hahn et al, 2006).…”

“…Of 28 pregnancies after the first trimester, exposed to doxorubicin and daunorubicin for the treatment of various hematologic malignancies, 21 pregnancies were delivered without any complications (Turchi and Villasis, 1988). The results of daunorubicin are worrying especially the combination with cytarabine which is associated with serious fetal morbidity and mortality (Azim et al, 2010). A stillborn fetus was reported in one case after exposure to daunorubicin.…”

Management of Concurrent Pregnancy and Acute Lymphoblastic Malignancy in Teenaged Patients: Two Illustrative Cases and Review of the Literature

“…20 However, the most commonly documented consequences during the late second or third trimester are intrauterine growth retardation, premature birth, and low birth weight. 26 Stillbirth and spontaneous abortion have also been reported, but are very rare after the first trimester.…”

“…2,4,13,19,20 Cytarabine exposure during the first trimester has been found to pose an 11% risk of congenital anomalies, 27 while second-and third-trimester exposure is associated with increased risk of prematurity, low birth weight, and possibly intrauterine fetal demise. 12,26 Imatinib, the prototype tyrosine kinase inhibitor, has been teratogenic in animal studies. Selig et al reported the largest review of human teratogenic effects of chemotherapeutic agents; they included 24 cases of imatinib exposure during pregnancy, which had a 21% cumulative incidence of adverse pregnancy outcome.…”